IP Library › Granted Patent US 12,201,680
Granted Patent B2
US 12,201,680 · App. 17/139,778 · Granted Jan 21, 2025

Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen

Inventors: Andreas Thess (Kusterdingen, DE); Thomas Schlake (Gundelfingen, DE); Jochen Probst (Wolfschlugen, DE)
Assignee: CureVac SE
A61K39/145A61K39/00A61K39/12C12N7/00C12N15/63C12N15/67A61K2039/53A61K2039/64C12N2760/16134C12N2770/20034C12N2830/50Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,680
App. No.
17/139,778
Granted
Jan 21, 2025
Kind
B2
Abstract

The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

Claims (23)

1. A method of stimulating an immune response in a subject comprising administering an effective amount a composition to the subject, said composition comprising a mRNA encoding a Severe Acute Respiratory Syndrome (SARS) coronavirus spike(S) protein coding sequence and a histone stem loop sequence, said mRNA provided in complex with a lipid.

2. The method of claim 1 , wherein the composition is administered by intradermal or intramuscular injection.

3. The method of claim 2 , wherein the composition is administered by intramuscular injection.

4. The method of claim 1 , wherein the mRNA comprises a Poly-A sequence.

5. The method of claim 4 , wherein the mRNA comprises a Poly-A sequence of about 25 to 400 adenosine nucleotides.

6. The method of claim 1 , wherein the mRNA comprises a 5′ untranslated region (UTR) and/or a 3′ UTR.

7. The method of claim 6 , wherein the mRNA comprises a 5′UTR and a 3′ UTR.

8. The method of claim 1 , wherein the lipid comprises a cationic lipid.

9. The method of claim 1 , wherein the coding sequence of the mRNA has a G/C content that is increased compared with the G/C content of the coding sequence of a wild-type RNA.

10. The method of claim 1 , wherein the mRNA comprises a nucleotide analog substitution.

11. The method of claim 10 , wherein the nucleotide analog substation comprises at least one pseudouridine-5′-triphosphate substitution.

12. The method of claim 1 , wherein the mRNA comprises a methylated 5′ cap.

13. The method of claim 1 , further comprising a polyethyleneglycol.

14. The method of claim 1 , further comprising an adjuvant.

15. The method of claim 1 , wherein the mRNA comprises a methylated 5′ cap; a 5′ UTR; a 3′ UTR and a Poly-A sequence of about 25 to 400 adenosine nucleotides.

16. The method of claim 15 , wherein the coding sequence of the mRNA has a G/C content that is increased compared with the G/C content of the coding sequence of a wild-type RNA.

17. The method of claim 16 , wherein the lipid comprises a cationic lipid.

18. The method of claim 1 , wherein the histone stem loop sequence is at least 90% identical to the sequence of SEQ ID NO: 39 or SEQ ID NO: 42.

19. The method of claim 18 , wherein the histone stem loop sequence is at least 90% identical to the sequence of SEQ ID NO: 39.

20. A method of stimulating an immune response in a subject comprising administering an effective amount a composition to the subject, said composition comprising a purified mRNA encoding: a 5′ UTR; a coronaviruses spike(S) protein coding sequence; a 3′ UTR; a Poly-A sequence of 25 to 400 adenosine nucleotides; and a histone stem loop sequence, said mRNA comprising a 5′ Cap, wherein the purified mRNA is provided in complex with a lipid.

21. The method of claim 20 , wherein the composition is administered by intradermal or intramuscular injection.

22. The method of claim 21 , wherein the lipid comprises a cationic lipid.

23. The method of claim 20 , wherein the coding sequence of the mRNA has a G/C content that is increased compared with the G/C content of the coding sequence of a wild-type RNA.

Assignments (1)
CHANGE OF NAME Recorded Jan 11, 2023
From: CUREVAC AG
To: CUREVAC SE
Reel/Frame 062356/0473 →
Continuity (6)
Division 16938136 · Jul 24, 2020
Continuation 15892330 · Feb 8, 2018
Continuation 15465322 · Mar 21, 2017
Continuation 14378538
Continuation PCTEP2012000673 · Feb 15, 2012
Related Publication 20210128716A1 · May 6, 2021
References Cited (400)
US 5908779A · Carmichael et al. · 1999 [cited by applicant]
US 6783961B1 · Edwards et al. · 2004 [cited by applicant]
US 6822072B1 · Edwards et al. · 2004 [cited by applicant]
US 7432049B2 · Liew et al. · 2008 [cited by applicant]
US 7700359B2 · Chan et al. · 2010 [cited by applicant]
US 8217016B2 · Hoerr et al. · 2012 [cited by applicant]
US 8383340B2 · Ketterer et al. · 2013 [cited by applicant]
US 8703906B2 · Baumhof et al. · 2014 [cited by applicant]
US 8968746B2 · Baumhof et al. · 2015 [cited by applicant]
US 9155788B2 · Hoerr et al. · 2015 [cited by applicant]
US 9226959B2 · Kramps et al. · 2016 [cited by applicant]
US 9234013B2 · Thess et al. · 2016 [cited by applicant]
US 9314535B2 · Baumhof et al. · 2016 [cited by applicant]
US 9352028B2 · Barner et al. · 2016 [cited by applicant]
US 9402887B2 · Probst et al. · 2016 [cited by applicant]
US 9421255B2 · Baumhof et al. · 2016 [cited by applicant]
US 9433669B2 · Hoerr et al. · 2016 [cited by applicant]
US 9433670B2 · Hoerr et al. · 2016 [cited by applicant]
US 9439956B2 · Hoerr et al. · 2016 [cited by applicant]
US 9447431B2 · Thess et al. · 2016 [cited by applicant]
US 9463228B2 · Hoerr et al. · 2016 [cited by applicant]
US 9572874B2 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 9616084B2 · Mutzke · 2017 [cited by applicant]
US 9623095B2 · Kallen et al. · 2017 [cited by applicant]
US 9655955B2 · Hoerr et al. · 2017 [cited by applicant]
US 9669089B2 · Thess et al. · 2017 [cited by applicant]
US 9683233B2 · Thess · 2017 [cited by applicant]
US 9688729B2 · Kramps et al. · 2017 [cited by applicant]
US 9737595B2 · Lorenz et al. · 2017 [cited by applicant]
US 9839697B2 · Thess et al. · 2017 [cited by applicant]
US 9890391B2 · Thess et al. · 2018 [cited by applicant]
US 9907862B2 · Baumhof et al. · 2018 [cited by applicant]
US 9974845B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10010592B2 · Thess et al. · 2018 [cited by applicant]
US 10017826B2 · von der Mülbe et al. · 2018 [cited by applicant]
US 10047375B2 · Thess · 2018 [cited by applicant]
US 10080809B2 · Thess · 2018 [cited by applicant]
US 10111967B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10111968B2 · Thess et al. · 2018 [cited by applicant]
US 10117920B2 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 10150797B2 · Kramps et al. · 2018 [cited by applicant]
US 10166283B2 · Thess et al. · 2019 [cited by applicant]
US 10172935B2 · Kallen et al. · 2019 [cited by applicant]
US 10188748B2 · Von der Mülbe et al. · 2019 [cited by applicant]
US 10232024B2 · Thess et al. · 2019 [cited by applicant]
US 10293058B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10293060B2 · Baumhof · 2019 [cited by applicant]
US 10307472B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10369216B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10434154B2 · Probst et al. · 2019 [cited by applicant]
US 10434158B2 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 10441653B2 · Hoerr et al. · 2019 [cited by applicant]
US 10501768B2 · Eber et al. · 2019 [cited by applicant]
US 10517827B2 · Eber et al. · 2019 [cited by applicant]
US 10568958B2 · Baumhof et al. · 2020 [cited by applicant]
US 10568972B2 · Von der Mülbe et al. · 2020 [cited by applicant]
US 10588959B2 · Kallen et al. · 2020 [cited by applicant]
US 10596252B2 · Kallen et al. · 2020 [cited by applicant]
US 10610605B2 · Thess et al. · 2020 [cited by applicant]
US 10648017B2 · Wochner · 2020 [cited by applicant]
US 10653768B2 · Mutzke et al. · 2020 [cited by applicant]
US 10653799B2 · Thess et al. · 2020 [cited by applicant]
US 10682406B2 · Thess et al. · 2020 [cited by applicant]
US 10682426B2 · Schnee et al. · 2020 [cited by applicant]
US 10702600B1 · Ciaramella et al. · 2020 [cited by applicant]
US 10711315B2 · von der Mülbe et al. · 2020 [cited by applicant]
US 10729654B2 · Eber et al. · 2020 [cited by applicant]
US 10729761B2 · Kallen et al. · 2020 [cited by applicant]
US 10738306B2 · Thess · 2020 [cited by applicant]
US 10751424B2 · Baumhof et al. · 2020 [cited by applicant]
US 10760070B2 · Funkner et al. · 2020 [cited by applicant]
US 10780054B2 · Ketterer et al. · 2020 [cited by applicant]
US 10799577B2 · Thess et al. · 2020 [cited by applicant]
US 10799602B2 · Baumhof · 2020 [cited by applicant]
US 10837039B2 · Wochner et al. · 2020 [cited by applicant]
US 10869935B2 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 10898584B2 · Schlake et al. · 2021 [cited by applicant]
US 10898589B2 · Thess et al. · 2021 [cited by applicant]
US 10912826B2 · Thess et al. · 2021 [cited by applicant]
US 10918740B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 10988754B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11034729B2 · Kramps et al. · 2021 [cited by applicant]
US 11078247B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110156B2 · Thess et al. · 2021 [cited by applicant]
US 11110157B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11110166B2 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 11135312B2 · von der Mülbe et al. · 2021 [cited by applicant]
US 11141474B2 · Rauch et al. · 2021 [cited by applicant]
US 11141476B2 · Rauch · 2021 [cited by applicant]
US 11149278B2 · Thess et al. · 2021 [cited by applicant]
US 11179337B2 · Eber et al. · 2021 [cited by applicant]
US 11225682B2 · Reichert et al. · 2022 [cited by applicant]
US 11241493B2 · Rauch et al. · 2022 [cited by applicant]
US 11248223B2 · Yazdan Panah et al. · 2022 [cited by applicant]
US 11254951B2 · Thess · 2022 [cited by applicant]
US 11266735B2 · Kallen et al. · 2022 [cited by applicant]
US 11268157B2 · von der Mülbe et al. · 2022 [cited by applicant]
US 11274293B2 · Funkner et al. · 2022 [cited by applicant]
US 11279923B2 · Funkner et al. · 2022 [cited by applicant]
US 11286492B2 · Thess et al. · 2022 [cited by applicant]
US 20040038405A1 · Liu et al. · 2004 [cited by applicant]
US 20050009028A1 · Heintz et al. · 2005 [cited by applicant]
US 20050032730A1 · Von Der Mülbe et al. · 2005 [cited by applicant]
US 20050048549A1 · Cao et al. · 2005 [cited by applicant]
US 20050059624A1 · Hoerr et al. · 2005 [cited by applicant]
US 20050250723A1 · Hoerr et al. · 2005 [cited by applicant]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20070111203A1 · Cao et al. · 2007 [cited by applicant]
US 20070172949A9 · Liu et al. · 2007 [cited by applicant]
US 20070280929A1 · Hoerr et al. · 2007 [cited by applicant]
US 20080025944A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080171711A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080267873A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090324584A1 · Hoerr et al. · 2009 [cited by applicant]
US 20100047261A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100048883A1 · Ketterer et al. · 2010 [cited by applicant]
US 20100120152A1 · Wooddell et al. · 2010 [cited by applicant]
US 20100129392A1 · Shi et al. · 2010 [cited by applicant]
US 20100189729A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20100239608A1 · Von Der Mülbe et al. · 2010 [cited by applicant]
US 20100291156A1 · Barner et al. · 2010 [cited by applicant]
US 20100303851A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100305196A1 · Probst et al. · 2010 [cited by applicant]
US 20110053829A1 · Baumhof et al. · 2011 [cited by applicant]
US 20110077287A1 · Von Der Mülbe et al. · 2011 [cited by applicant]
US 20110250225A1 · Fotin-Mleczek et al. · 2011 [cited by applicant]
US 20110269950A1 · Von Der Mülbe et al. · 2011 [cited by applicant]
US 20110311472A1 · Hoerr et al. · 2011 [cited by applicant]
US 20120009221A1 · Hoerr et al. · 2012 [cited by applicant]
US 20120021043A1 · Kramps et al. · 2012 [cited by applicant]
US 20120213818A1 · Hoerr et al. · 2012 [cited by applicant]
US 20120258046A1 · Mutzke · 2012 [cited by applicant]
US 20130121988A1 · Hoerr et al. · 2013 [cited by applicant]
US 20130129754A1 · Thess et al. · 2013 [cited by applicant]
US 20130142818A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130195867A1 · Hoerr et al. · 2013 [cited by applicant]
US 20130202645A1 · Barner et al. · 2013 [cited by applicant]
US 20130251742A1 · Probst et al. · 2013 [cited by applicant]
US 20130259879A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130273001A1 · Hoerr et al. · 2013 [cited by applicant]
US 20130280283A1 · Lorenz et al. · 2013 [cited by applicant]
US 20130295043A1 · Kallen et al. · 2013 [cited by applicant]
US 20130336998A1 · Kallen et al. · 2013 [cited by applicant]
US 20140037660A1 · Fotin-Mleczek et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140294877A1 · Baumhof et al. · 2014 [cited by applicant]
US 20150037326A1 · Butler-Ransohoff et al. · 2015 [cited by applicant]
US 20150050302A1 · Thess · 2015 [cited by applicant]
US 20150057340A1 · Thess et al. · 2015 [cited by applicant]
US 20150093413A1 · Thess · 2015 [cited by applicant]
US 20150104476A1 · Von Der Mülbe et al. · 2015 [cited by applicant]
US 20150118183A1 · Baumhof · 2015 [cited by applicant]
US 20150118264A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150141498A1 · Mutzke · 2015 [cited by applicant]
US 20150165006A1 · Thess et al. · 2015 [cited by applicant]
US 20150184195A1 · Thess et al. · 2015 [cited by applicant]
US 20150218554A1 · Thess · 2015 [cited by applicant]
US 20150258214A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150306249A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150320847A1 · Thess et al. · 2015 [cited by applicant]
US 20160130345A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20160151474A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166668A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166678A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166710A1 · Baumhof · 2016 [cited by applicant]
US 20160166711A1 · Schnee et al. · 2016 [cited by applicant]
US 20160168207A1 · Kramps et al. · 2016 [cited by applicant]
US 20160168227A1 · Kallen et al. · 2016 [cited by applicant]
US 20160235864A1 · Schlake et al. · 2016 [cited by applicant]
US 20160304883A1 · Grund et al. · 2016 [cited by applicant]
US 20160304938A1 · Wochner · 2016 [cited by applicant]
US 20160326575A1 · von der Mülbe · 2016 [cited by applicant]
US 20160331844A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170114378A1 · Wochner et al. · 2017 [cited by applicant]
US 20170182150A1 · Kallen et al. · 2017 [cited by applicant]
US 20170239372A1 · Baumhof et al. · 2017 [cited by applicant]
US 20170252430A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170266268A1 · Kallen et al. · 2017 [cited by applicant]
US 20170326225A1 · Rauch et al. · 2017 [cited by applicant]
US 20170340725A1 · Ciaramella et al. · 2017 [cited by applicant]
US 20180044687A1 · Thess et al. · 2018 [cited by applicant]
US 20180078629A1 · Lorenz et al. · 2018 [cited by applicant]
US 20180125952A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180126003A1 · Hoerr · 2018 [cited by applicant]
US 20180126005A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180142275A1 · Roos et al. · 2018 [cited by applicant]
US 20180148727A1 · Grund et al. · 2018 [cited by applicant]
US 20180207295A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180208957A1 · Roos et al. · 2018 [cited by applicant]
US 20180237786A1 · Schlake et al. · 2018 [cited by applicant]
US 20180237817A1 · Roos et al. · 2018 [cited by applicant]
US 20180256694A1 · Barner et al. · 2018 [cited by applicant]
US 20180296663A1 · Hipp et al. · 2018 [cited by applicant]
US 20180312545A1 · Baumhof et al. · 2018 [cited by applicant]
US 20180371392A1 · Mayer et al. · 2018 [cited by applicant]
US 20190008954A1 · Baumhof · 2019 [cited by applicant]
US 20190017100A1 · Wochner et al. · 2019 [cited by applicant]
US 20190024096A1 · Schmid et al. · 2019 [cited by applicant]
US 20190049414A1 · Wochner et al. · 2019 [cited by applicant]
US 20190083602A1 · Roos et al. · 2019 [cited by applicant]
US 20190100784A1 · Eber et al. · 2019 [cited by applicant]
US 20190151438A1 · Kallen et al. · 2019 [cited by applicant]
US 20190160164A1 · Rauch et al. · 2019 [cited by applicant]
US 20190177714A1 · Kunze et al. · 2019 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190194760A1 · Koch et al. · 2019 [cited by applicant]
US 20190225971A1 · Williams · 2019 [cited by applicant]
US 20190255161A1 · Thess et al. · 2019 [cited by applicant]
US 20190336608A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190336611A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190343933A1 · Horscroft et al. · 2019 [cited by applicant]
US 20190343942A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190345504A1 · Grund et al. · 2019 [cited by applicant]
US 20190351044A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20190365879A1 · Probst et al. · 2019 [cited by applicant]
US 20190381155A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190381180A1 · Baumhof et al. · 2019 [cited by applicant]
US 20200016264A1 · Hoerr et al. · 2020 [cited by applicant]
US 20200023076A1 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 20200040370A1 · Eber et al. · 2020 [cited by applicant]
US 20200085852A1 · Fotin-Mleczek · 2020 [cited by applicant]
US 20200085942A1 · Kramps et al. · 2020 [cited by applicant]
US 20200085943A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200085944A1 · Heidenreich et al. · 2020 [cited by applicant]
US 20200149026A1 · Horscroft et al. · 2020 [cited by applicant]
US 20200163878A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200179526A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200197510A1 · Ciaramella et al. · 2020 [cited by applicant]
US 20200216878A1 · Wochner · 2020 [cited by applicant]
US 20200246451A1 · Mutzke et al. · 2020 [cited by applicant]
US 20200268908A1 · Schnee et al. · 2020 [cited by applicant]
US 20200276336A1 · Thess et al. · 2020 [cited by applicant]
US 20200316189A1 · Kallen et al. · 2020 [cited by applicant]
US 20200332293A1 · Thess · 2020 [cited by applicant]
US 20200338215A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200383919A1 · Eber et al. · 2020 [cited by applicant]
US 20200383922A1 · Ketterer et al. · 2020 [cited by applicant]
US 20200392572A1 · Yazdan Panah et al. · 2020 [cited by applicant]
US 20200399322A1 · Baumhof et al. · 2020 [cited by applicant]
US 20210023199A1 · Kallen et al. · 2021 [cited by applicant]
US 20210030683A1 · Eber et al. · 2021 [cited by applicant]
US 20210030864A1 · Petsch et al. · 2021 [cited by applicant]
US 20210030866A1 · Kallen et al. · 2021 [cited by applicant]
US 20210040526A1 · Wochner et al. · 2021 [cited by applicant]
US 20210046179A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210060175A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210060181A1 · Thess et al. · 2021 [cited by applicant]
US 20210069315A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210128716A1 · Thess et al. · 2021 [cited by applicant]
US 20210162037A1 · Jasny et al. · 2021 [cited by applicant]
US 20210170017A1 · Lutz et al. · 2021 [cited by applicant]
US 20210180106A1 · Wochner et al. · 2021 [cited by applicant]
US 20210187124A1 · Schlake et al. · 2021 [cited by applicant]
US 20210198649A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210205434A1 · Petsch et al. · 2021 [cited by applicant]
US 20210222178A1 · Linke et al. · 2021 [cited by applicant]
US 20210251898A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210260178A1 · Jasny et al. · 2021 [cited by applicant]
US 20210261627A1 · Kramps et al. · 2021 [cited by applicant]
US 20210261897A1 · Yazdan Panah et al. · 2021 [cited by applicant]
US 20210308238A1 · Hoerr et al. · 2021 [cited by applicant]
US 20210361761A1 · Lutz et al. · 2021 [cited by applicant]
US 20210361764A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210369827A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210393755A1 · Thess et al. · 2021 [cited by applicant]
US 20210401966A1 · Rauch et al. · 2021 [cited by applicant]
US 20210401971A1 · Rauch · 2021 [cited by applicant]
US 20210403925A1 · Chevessier-Tünnesen et al. · 2021 [cited by applicant]
US 20220025369A1 · Fotin-Mleczek et al. · 2022 [cited by applicant]
US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]
US 20220073962A1 · Schwenger et al. · 2022 [cited by applicant]
US 20220090092A1 · Thess et al. · 2022 [cited by applicant]
US 20220096616A1 · Barner et al. · 2022 [cited by applicant]
US 20220119795A1 · Yazdan Panah et al. · 2022 [cited by applicant]
US 20220133908A1 · Rejman et al. · 2022 [cited by applicant]
US 20220136011A1 · Thess · 2022 [cited by applicant]
US 20220144877A1 · Heinz et al. · 2022 [cited by applicant]
WO WO1995015394 · 1995 [cited by applicant]
WO WO1998042856 · 1998 [cited by applicant]
WO WO2001007590 · 2001 [cited by applicant]
WO WO2001012824 · 2001 [cited by applicant]
WO WO2002085434 · 2002 [cited by applicant]
WO WO2002098443 · 2002 [cited by applicant]
WO WO2003059381 · 2003 [cited by applicant]
WO WO2005035771 · 2005 [cited by applicant]
WO WO2005040377 · 2005 [cited by applicant]
WO WO2006008154 · 2006 [cited by applicant]
WO WO2006022712 · 2006 [cited by applicant]
WO WO2006024518 · 2006 [cited by applicant]
WO WO2006122828 · 2006 [cited by applicant]
WO WO2006123097 · 2006 [cited by applicant]
WO WO2007024708 · 2007 [cited by applicant]
WO WO2007068265 · 2007 [cited by applicant]
WO WO2008014979 · 2008 [cited by applicant]
WO WO2008077592 · 2008 [cited by applicant]
WO WO2008083949 · 2008 [cited by applicant]
WO WO2009030481 · 2009 [cited by applicant]
WO WO2009046974 · 2009 [cited by applicant]
WO WO2009046975 · 2009 [cited by applicant]
WO WO2009095226 · 2009 [cited by applicant]
WO WO2009127230 · 2009 [cited by applicant]
WO WO2009155961 · 2009 [cited by applicant]
WO WO2010023260 · 2010 [cited by applicant]
WO WO2010037539 · 2010 [cited by applicant]
WO WO2010088927 · 2010 [cited by applicant]
WO WO2010132867 · 2010 [cited by applicant]
WO WO2011026641 · 2011 [cited by applicant]
WO WO2011069528 · 2011 [cited by applicant]
WO WO2011069529 · 2011 [cited by applicant]
WO WO2011069586 · 2011 [cited by applicant]
WO WO2011069587 · 2011 [cited by applicant]
WO WO2011144358 · 2011 [cited by applicant]
WO WO2012013326 · 2012 [cited by applicant]
WO WO2012019630 · 2012 [cited by applicant]
WO WO2012019780 · 2012 [cited by applicant]
WO WO2012089338 · 2012 [cited by applicant]
WO WO2012113513 · 2012 [cited by applicant]
WO WO2012116714 · 2012 [cited by applicant]
WO WO2012116810 · 2012 [cited by applicant]
WO WO2012116811 · 2012 [cited by applicant]
WO WO2013113501 · 2013 [cited by applicant]
WO WO2013113502 · 2013 [cited by applicant]
WO WO2013113736 · 2013 [cited by applicant]
WO WO2013120626 · 2013 [cited by applicant]
WO WO2013120627 · 2013 [cited by applicant]
WO WO2013120628 · 2013 [cited by applicant]
WO WO2013120629 · 2013 [cited by applicant]
WO WO2013143698 · 2013 [cited by applicant]
WO WO2013143699 · 2013 [cited by applicant]
WO WO2013143700 · 2013 [cited by applicant]
WO WO2013174409 · 2013 [cited by applicant]
WO WO2014127917 · 2014 [cited by applicant]
WO WO2015024665 · 2015 [cited by applicant]
WO WO2015024668 · 2015 [cited by applicant]
WO WO2015062738 · 2015 [cited by applicant]
WO WO2015101414 · 2015 [cited by applicant]
WO WO2015101415 · 2015 [cited by applicant]
WO WO2015101416 · 2015 [cited by applicant]
WO WO2015135558 · 2015 [cited by applicant]
WO WO2015149944 · 2015 [cited by applicant]
WO WO2016107877 · 2016 [cited by applicant]
WO WO2016165825 · 2016 [cited by applicant]
WO WO2016165831 · 2016 [cited by applicant]
WO WO2016174227 · 2016 [cited by applicant]
WO WO2016174271 · 2016 [cited by applicant]
WO WO2016184575 · 2016 [cited by applicant]
WO WO2016184576 · 2016 [cited by applicant]
WO WO2016184822 · 2016 [cited by applicant]
WO WO2016193206 · 2016 [cited by applicant]
WO WO2016193226 · 2016 [cited by applicant]
WO WO2016203025 · 2016 [cited by applicant]
WO WO2017001058 · 2017 [cited by applicant]
WO WO2017009376 · 2017 [cited by applicant]
WO WO2017021546 · 2017 [cited by applicant]
WO WO2017025120 · 2017 [cited by applicant]
WO WO2017025447 · 2017 [cited by applicant]
WO WO2017036580 · 2017 [cited by applicant]
Attwood, “The babel of bioinformatics,” [cited by applicant]
Avni et al., “The 5′ terminal oligopyrimidine tract confers translational control on TOP mRNAs in a cell type-and sequence context-dependent manner,” [cited by applicant]
Avni et al., “Vertebrate mRNAs with a 5′-terminal pyrimidine tract are candidates for translational repression in quiescent cells: characterization of the translational cis-regulatory element,” [cited by applicant]
Battle and Doudna, “The stem-loop binding protein forms a highly stable and specific complex with the 3′ stem-loop of histone mRNAs”, [cited by applicant]
Blumenthal et al., “Definition of an allergen (immunobiology),” [cited by applicant]
Caldarola et al., “Translational regulation of terminal oligopyrimidine mRNAs induced by serum and amino acids involves distinct signaling events,” [cited by applicant]
Cameron et al., “Recent advances in transgenic technology,” [cited by applicant]
Chakrabarti et al., “The mammalian target of rapamycin complex 1 regulates leptin biosynthesis in adipocytes at the level of translation: the role of the 5′-untranslated region in the expression of leptin messenger ribo… [cited by applicant]
Cheung et al., “Specific interaction of HeLa cell proteins with coxsackievirus B3 3′UTR: La autoantigen binds the 3′ and 5′ UTR independently of the poly(A) tail,” [cited by applicant]
Collart et al., “A human histone H2B.1 variant gene, located on chromosome 1, utilizes alternative 3′ end processing”, [cited by applicant]
Damgaard and Lykke-Andersen, “Translational coregulation of 5′TOP mRNAs by TIA-1 and TIAR,” [cited by applicant]
Database EMBL Accession No. EM_STD:AB063609, “ [cited by applicant]
Database GenBank, [online], Accession No. AK222475, Nov. 17, 2007, <https://www.ncbi.nlm.nih.gov/nuccore/62896508?sat=46&satkey=15856460>. [cited by applicant]
Database GenBank, [online], Accession No. AK222780, Nov. 17, 2007, <https://www.ncbi.nlm.nih.gov/nuccore/62897118?sat=46&satkey=15856751>. [cited by applicant]
Database GenBank, [online], Accession No. D28385, Mar. 10, 2009, <https://www.ncbi.nlm.nih.gov/nuccore/461233?sat=46&satkey=15629526>. [cited by applicant]
Database GenBank, [online], Accession No. D28406, Jan. 22, 2005, <https://www.ncbi.nlm.nih.gov/nuccore/461241?sat=46&satkey=15629534>. [cited by applicant]
Database GenBank, [online], Accession No. D28448, Jan. 22, 2005, <https://www.ncbi.nlm.nih.gov/nuccore/461226?sat=46&satkey=15629520>. [cited by applicant]
Database GenBank, [online], Accession No. NM_001199291, Mar. 5, 2012, <https://www.ncbi.nlm.nih.gov/nuccore/313482809?sat=15&satkey=6403420>. [cited by applicant]
Database GenBank, [online], Accession No. NM_004046, Mar. 24, 2012, <https://www.ncbi.nlm.nih.gov/nuccore/50345980?sat=15&satkey=6379190>. [cited by applicant]
Database GenBank, [online], Accession No. NM_004374, Jan. 23, 2012, <https://www.ncbi.nlm.nih.gov/nuccore/301069354?sat=15&satkey=6401626>. [cited by applicant]
Database Geneseq Accession No. ATN08647, “Human transcriptional regulatory element Seq ID No. 6587,” 2008. [cited by applicant]
Database Nucleotide, “Human ribosomal protein L9 mRNA, complete cds,” XP002729678, Database accession No. U09953.1, 1996. [cited by applicant]
Davuluri et al., “CART classification of human 5′ UTR sequences,” [cited by applicant]
Declaration Under 37 C.F.R. § 1.132, submitted in U.S. Appl. No. 15/195,934, filed Feb. 9, 2018. [cited by applicant]
Deml et al., “Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein,” Journal of Virology, 75(22):10991-1100… [cited by applicant]
Dhamija et al., “IL-1-induced Post-transcriptional Mechanisms Target Overlapping Translational Silencing and Destabilizing Elements in IKBC mRNA,” J. Biol. Chem., 285(38):29165-29178, 2010. [cited by applicant]
Dollé et al., “Nerve growth factor overexpression and autocrine loop in breast cancer cells,” [cited by applicant]
Dominski et al., “Stem-loop binding protein facilitates 3′-end formation by stabilizing U7 snRNP binding to histone pre-mRNA,” [cited by applicant]
Dugaiczyk et al., “Nucleotide sequence and the encoded amino acids of human serum albumin mRNA,” [cited by applicant]
Eckner et al., “Mature mRNA 3′ end formation stimulates RNA export from the nucleus,” [cited by applicant]
Gallie et al., “The histone 3′-terminal stem-loop is necessary for translation in Chinese hamster ovary cells”, [cited by applicant]
Gerwitz et al., “Nucleic acid therapeutics: state of the art and future prospects,” [cited by applicant]
Ginn et al., “Gene therapy clinical trails worldwide to 2012—an update,” [cited by applicant]
Gorgoni et al., “The stem-loop binding protein stimulates histone translation at an early step in the initiation pathway,” [cited by applicant]
Haines et al., “CL22—a novel cationic peptide for efficient transfection of mammalian cells,” [cited by applicant]
Henke et al., “Coxsackievirus B3 vaccines: use as an expression vector for prevention of myocarditis,” [cited by applicant]
Hoeksema et al., “Placing the RPL32 Promoter Upstream of a Second Promoter Results in a Strongly Increased Number of Stably Transfected Mammalian Cell Lines That Display High Protein Expression Levels,” Biotechnol. Res.… [cited by applicant]
Holtkamp et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells”, [cited by applicant]
Iadevaia et al., “All translation elongation factors and the e, f, and h subunits of translation initiation factor 3 are encoded by 5′-terminal oligopyrimidine (TOP) mRNAs,” [cited by applicant]